9.65
-0.46(-4.55%)
Currency In USD
| Previous Close | 10.11 |
| Open | 9.99 |
| Day High | 9.99 |
| Day Low | 9.33 |
| 52-Week High | 46.8 |
| 52-Week Low | 3.76 |
| Volume | 57,533 |
| Average Volume | 85,111 |
| Market Cap | 59.38M |
| PE | -0.71 |
| EPS | -13.54 |
| Moving Average 50 Days | 9.32 |
| Moving Average 200 Days | 8.34 |
| Change | -0.46 |
If you invested $1000 in Aligos Therapeutics, Inc. (ALGS) since IPO date, it would be worth $25.99 as of December 30, 2025 at a share price of $9.65. Whereas If you bought $1000 worth of Aligos Therapeutics, Inc. (ALGS) shares 3 years ago, it would be worth $405.12 as of December 30, 2025 at a share price of $9.65.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aligos Therapeutics Presents Positive Data at HEP-DART 2025
GlobeNewswire Inc.
Dec 11, 2025 1:00 PM GMT
Oral presentation of ALG-055009 in vivo nonclinical data showcases synergistic fat mass loss in combination with incretin receptor agonists SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025
GlobeNewswire Inc.
Nov 10, 2025 1:00 PM GMT
Oral presentation of 96-week treatment and post-treatment data suggest best-in-class potential of pevifoscorvir sodiumSOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharm
Aligos Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 04, 2025 1:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, t